Metabolic dysfunction-associated fatty liver disease and risk of incident chronic kidney disease: A nationwide cohort study - 27/07/22
, Seung Up Kim a, b, ⁎ Abstract |
Aims |
The recently proposed metabolic dysfunction-associated fatty liver disease (MAFLD) has been suggested to better reflect the metabolic components of fatty liver disease (FLD), compared to nonalcoholic fatty liver disease (NAFLD). This study investigated whether MAFLD identifies a higher proportion of individuals at risk of developing chronic kidney disease (CKD).
Methods |
268,946 participants aged 40–64 years, who underwent National Health Insurance Service health examinations between 2009 and 2015 were included. Participants were categorized by presence of FLD, according to MAFLD or NAFLD. In participants with FLD, participants were categorized into three groups: non-metabolic risk (non-MR) NAFLD, MAFLD but not NAFLD, and overlapping FLD. Incident CKD was defined as the occurrence of eGFR < 60 mL/min/1.73m2 or proteinuria (≥ trace) on two consecutive health examinations.
Results |
73,726 (27.4%) and 88,762 (33.0%) participants had NAFLD and MAFLD, respectively. During a median follow-up of 5.1 years, CKD occurred in 8,335 (6.2/1,000 person-years) participants. Compared to non-NAFLD participants, the adjusted hazard ratio (aHR) for incident CKD was 1.33 (95% CI, 1.27–1.39; P < 0.001) for participants with NAFLD. Compared to non-MAFLD participants, the aHR for participants with MAFLD was 1.39 (95% CI, 1.33–1.46; P < 0.001). When the analysis was confined to participants with FLD, compared to non-MR NAFLD participants, the aHRs for participants with MAFLD but not NAFLD, and those with overlapping FLD were 1.18 (95% CI, 1.01–1.39; P = 0.040) and 1.36 (95% CI, 1.19–1.54; P < 0.001), respectively.
Conclusion |
MAFLD identified a higher proportion of individuals at risk of developing CKD than NAFLD.
Le texte complet de cet article est disponible en PDF.Keywords : Chronic kidney disease, Metabolic dysfunction-associated fatty liver disease, Nonalcoholic fatty liver disease, Outcomes, Risk factors
Abbreviations : NAFLD, CKD, CVD, ESKD, MAFLD, FLD, NHIS, eGFR, FLI, BMI, MR, NSAIDs, HR, CI, LDL, AST, ALT, HSI, NHANES
Plan
Vol 48 - N° 4
Article 101344- juillet 2022 Retour au numéro
Article précédent
- The triglycerides and glucose (TyG) index: A new marker associated with nonalcoholic steatohepatitis (NASH) in obese patients
- Benjamin Rivière, Audrey Jaussent, Valérie Macioce, Stéphanie Faure, Nicolas Builles, Patrick Lefebvre, Philippe Géraud, Marie-Christine Picot, Sandra Rebuffat, Eric Renard, Valérie Paradis, Marie-Dominique Servais, Nathalie de Preville, David Nocca, Anne-Dominique Lajoix, Georges-Philippe Pageaux, Florence Galtier, COMET study group
- Epigenetic changes associated with hyperglycaemia exposure in the longitudinal D.E.S.I.R. cohort
- Amna Khamis, Lijiao Ning, Beverley Balkau, Amélie Bonnefond, Mickaël Canouil, Ronan Roussel, Philippe Froguel
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?